登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由苏州大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT04025450,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
RISS-3;
入选标准第 3 条
8.Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1;
入选标准第 16 条
2.Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed;
排除标准第 2 条
4.ECOG 0-2 points, with life expectance ≥3 months; GA score <2;
入选标准第 12 条
5.ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum;
入选标准第 13 条
6.Neutrophil count≥1.5×109/L, platelet count≥50×109/L;
入选标准第 14 条
7.eGFR≥40ml/min,except in the case of myeloma-related nephropathy;
入选标准第 15 条
2.Secretory MM should have measurable markers, including:
入选标准第 7 条
and/or measurable extramedullary foci (diameter>1cm on CT);
入选标准第 10 条
9.With active hepatitis;
排除标准第 9 条
10.HIV positive;
排除标准第 10 条
11.History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma;
排除标准第 11 条
4.Patients in pregnancy or lactation;
排除标准第 4 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04025450,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1.Diagnosed as multiple myeloma, and has one of the above: high risk karyotype, such as 17p-,t(4;14),t(14;16),t(14;20)或1q gain,1p-, double hit myeloma, triple hit myeloma, etc; RISS-3; IgD/IgE MM; with measurable extra-medullary plasmacytoma; flowcytometry showed peripheral blood plasma cell ≥0.165%; 2.Secretory MM should have measurable markers, including: specific M protein value (≥5g/L); and/or involved flc ≥100mg/L; and/or measurable extramedullary foci (diameter>1cm on CT); 3.Age≥18 years, male or female; 4.ECOG 0-2 points, with life expectance ≥3 months; GA score <2; 5.ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum; 6.Neutrophil count≥1.5×109/L, platelet count≥50×109/L; 7.eGFR≥40ml/min,except in the case of myeloma-related nephropathy; 8.Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1; 9.Willing to accept the possibility of potential adverse events and efficacy observation by the investigators; 10.Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial.排除标准:Exclusion Criteria:
1.With ≥2 degree of peripheral neuropath or with pain; 2.Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed; 3.With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction; 4.Patients in pregnancy or lactation; 5.Allergic constitution or being allergic to any drug within the regimen of the trial; 6.With uncontrolled mental diseases; 7.With active infection; 8.With non-myeloma-associated acute renal dysfunction; 9.With active hepatitis; 10.HIV positive; 11.History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma; 12.With other conditions that the investigators think unfit for the trial.
引自 ClinicalTrials.gov, NCT04025450, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04025450,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。